Invention Grant
- Patent Title: URLC10-derived peptide and vaccine containing same
-
Application No.: US15500895Application Date: 2015-07-31
-
Publication No.: US10576097B2Publication Date: 2020-03-03
- Inventor: Takuya Tsunoda , Ryuji Osawa , Sachiko Yamashita , Tomohisa Watanabe , Tetsuro Hikichi
- Applicant: ONCOTHERAPY SCIENCE, INC.
- Applicant Address: JP Kawasaki-Shi, Kanagawa
- Assignee: ONCOTHERAPY SCIENCE, INC.
- Current Assignee: ONCOTHERAPY SCIENCE, INC.
- Current Assignee Address: JP Kawasaki-Shi, Kanagawa
- Agency: Kilpatrick Townsend & Stockton LLP
- Priority: JP2014-158925 20140804
- International Application: PCT/JP2015/071839 WO 20150731
- International Announcement: WO2016/021510 WO 20160211
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K31/7088 ; A61K38/00 ; A61K48/00 ; C12N15/09 ; C07K7/06 ; C07K7/08 ; C12Q1/02 ; G01N33/15 ; G01N33/50

Abstract:
The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
Public/Granted literature
- US20180042954A1 URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME Public/Granted day:2018-02-15
Information query